Company profile · Wroclaw, Poland

Bioceltix

Veterinary Biologics, Cell Therapy, Animal Health, and Allogeneic Product Development · Veterinary biologics platform

Verified 15 Mar 2026 · 3 sources

BiologicsCell TherapyDiscovery

Veterinary cell-therapy and biologics node extending Wroclaw into advanced animal-health product development.

Lead
Łukasz Bzdzion (verified ↗)
Compliance
GLP
Last reviewed
15 Mar 2026 (3mo ago)
Scale
Veterinary biologics platform
Capabilities
Veterinary biologics development · Cell-therapy platform research · Animal-health product design
Founded
2018
Headcount
11-50
Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Łukasz Bzdzion

President of the Management Board

Check official leadership source
Full addressul. Bierutowska 57-59, bud. III, 51-317 Wroclaw, Poland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source

Official Bioceltix contact page listing ul. Bierutowska 57-59, bud. III in Wroclaw.

Open source
Operating profile

Veterinary biologics platform

Wroclaw, Poland. Veterinary Biologics, Cell Therapy, Animal Health, and Allogeneic Product Development. Review completed on 15 Mar 2026.

2026 technical specializationVeterinary Biologics, Cell Therapy, Animal Health, and Allogeneic Product Development
Core capabilities
Veterinary biologics developmentCell-therapy platform researchAnimal-health product designPreclinical and translational execution
Governance

Polish and EU veterinary biologics and development framework

Biological-drug development quality systems, Veterinary therapeutics governance

Editorial note

Veterinary Biologics, Cell Therapy, Animal Health, and Allogeneic Product Development

Veterinary cell-therapy and biologics node extending Wroclaw into advanced animal-health product development.

Editorial note

Bioceltix broadens the Polish layer into veterinary biologics and cell-based therapeutics with an officially disclosed board president and current pipeline surface.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 15 March 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Veterinary biologics development
Cell-therapy platform research
Animal-health product design
Preclinical and translational execution
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidenceBioceltix official management-board page confirming Łukasz Bzdzion as President of the Management Board.Source origin: bioceltix.comOpen source
Supporting evidenceBioceltix official platform page describing veterinary biological-drug development.Source origin: bioceltix.comOpen source
Physical-site evidenceOfficial Bioceltix contact page listing ul. Bierutowska 57-59, bud. III in Wroclaw.Source origin: bioceltix.comOpen source
Infrastructure

Declared infrastructure

Cell-biology labs
Biologics development workflows
Veterinary translational platform
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
REVIEW IN PROGRESS 2026
GLP
VERIFIED ACTIVE 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

15 Mar 2026: Executive identity confirmed via official management disclosure.
15 Mar 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Bioceltix located?
Bioceltix operates from ul. Bierutowska 57-59, bud. III, 51-317 Wroclaw, Poland, Wroclaw, Poland.
Who runs Bioceltix?
Bioceltix is led by Łukasz Bzdzion, President of the Management Board. Verified 15 Mar 2026.
What does Bioceltix do?
Veterinary cell-therapy and biologics node extending Wroclaw into advanced animal-health product development. Core capabilities: Veterinary biologics development, Cell-therapy platform research, Animal-health product design, Preclinical and translational execution.
Editorial context

Related technical briefs

Briefs that name Wroclaw as a covered market or city.